Jesduvroq (Daprodustat) Patent Expiration, LOE Window & CMS Spending

Jesduvroq (Daprodustat) by GSK: FDA Orange Book core substance LOE 2038-03-13, 0 AB generics, $23K 2024 CMS Part D & Medicaid spend, and $938 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorGSK
FDA Application & PathwayN216951 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2038-03-13
Last Listed Patent or Exclusivity Date2038-03-13
Orange Book Patents (*PED Extensions)6 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$23K
2024 Medicare Part D Spend$23K
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($938 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for GSK across sibling Meru public-data platforms.